$RVVTF (copy) DD by ecomike - I do not recall whose post I

New Post Public Reply Private Reply Replies (0) Message Board
mc67
928
$RVVTF (copy) DD by ecomike - I do not recall whose post I found this pdf on, but here are my thoughts on $RVVTF and Bucillaime based on the paper, and my earlier DD.

RVVTF may turn out to be a MONSTER monster stock, way bigger than the Phase III Covid19 drug trial that is why I already bought shares the last 12 weeks.

Reviewing why I had already bought:

It's Bucillamine Rx Drug has a 30 year safety history of use in Japan and So. Korea as a Rheumatoid Arthritis drug, thus has potential for keeping the immune system from killing people that get Covid19 (thus the phase III EUA FDA trial). That is why I bought shares and went long the last 12+ weeks

But, from what I just read, it looks like (the theory is sound IMHO) it can also deactivate Corona Viruses, all of them, as well. If the trials show it can disable the ability of corona viruses like Covid19, to invade and infect and take over cells, that it needs to seize control of to replicate, that is going to be game changer huge, as Covid19 and its future descendants are here with us to stay now.

It is in the wild. It is a Virus, it will mutate, because that is what they do.

Vaccines may only be a 6 month fix, before annual or Bi-annual booster shots are needed.

Bucillamine would not be a one dose cure. But a take it for days, at the first signs and symptoms or positive test...,drug, world wide.

Moderna Vaccine may work longer, but that verdict is not in. And being the first sRNA vaccine there is no long term safety history yet (It may be the safest vaccine ever, or ???) compared to RVVTF's Bucillamine.

Market cap of RVVTF is under 50 Mil dollars (thus not a bloated way overvalued pig) and for a real Drug firm, that is re-purposing safe, low cost to produce existing drugs, that is crazy cheap.

It is a Canadian reporting Drug firm. Trades on Frankfurt, Canadian and piggy backed on US OTC stock exchanges.

Covid19 early clinical drug trial data on the Bucillamine is due in about 2 weeks. So the current rally may top in 2-3 weeks. $2 to $3 looks realistic and reasonable.

If the paper (link to the pdf copy is attached below), theory and data are proven correct, and if it can in fact disable the ability of Corona/Covid19 Virus to infect cells, $10/share is possible? That would give it a Billion dollar market cap.

Quote from the paper I linked:

Title: Binding of SARS-CoV-2 spike protein to ACE2 is disabled by thiol-based drugs; evidence
from in vitro SARS-CoV-2 infection studies.

Summary: Thiol-based drugs decrease binding of SARS-CoV-2 spike protein to its receptor and inhibit SARS-CoV-2 cell entry.

NAC-aka N-Acytyl Cysteine (It is a Thiol based supplement...that regenerates Glutathione, and is already part of some MD's battle plans being used to fight Covid19.

Bucillamine is 16 times more active than NAC in the Thiol group activity/ability...

Here is the 22 page paper (I found here 2 days ago, and Finally got to scan-read the first page. I will cut and paste more comments as I read the rest of the paper, when I have time, if what I read adds anything to this story that is note worthy).

I will be buying more shares of RVVTF based on this.

https://cdn.discordapp.com/attachments/462311...1.full.pdf

Revive Therapeutics Ltd. (RVVTF) Stock Research Links

RVVTF Board Company Profile Buy Rating Time & Sales News Filings Financials
$MJ
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Faith and Resilience in China: The Legacy of the Long March

Updated Category News Views 41

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note

Updated Category News Views 37

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Continue Reading
UEG's New Advisory Board: Elevating Patient Voices

Updated Category News Views 45

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Continue Reading
AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 30

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading
Antheia Secures $80M for Critical Medicine Onshoring

Updated Category News Views 34

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Continue Reading
Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 25

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading
Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 58

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading

Top 5 Most Recently Viewed Articles

Bill Gates' Crossroads: Choosing Microsoft Over Harvard

Updated Category News Views 113

Bill Gates' Pivotal Decision Bill Gates, the co-founder of Microsoft, embarked on an intense journey during the early days of his company. Initially, he aimed to balance the demands of his blossoming software business with his studies at Harvard University. However, as the pressure mounted, he encountered a crucial decision that would shape his future. Struggling Between...

Continue Reading
Ensurge Micropower Invites Shareholders to Subscribe for New Shares

Updated Category News Views 63

Ensurge Micropower Announces Final Day for Share Subscription Ensurge Micropower ASA, known for its groundbreaking advancements in microbattery technology, has set the stage for a significant opportunity for shareholders. The subscription period for its subsequent offering, which consists of up to 22,222,222 new shares, is coming to a close. For those interested in...

Continue Reading
MongoDB Faces Class Action for Alleged Securities Violations

Updated Category News Views 57

Legal Challenges Facing MongoDB, Inc. MongoDB, Inc. (“MongoDB” or “the Company”) is currently embroiled in a class action lawsuit concerning alleged breaches of securities laws. This situation has sparked considerable concern among shareholders and investors about the company's transparency and the reliability of its financial practices. Overview of Allegations...

Continue Reading
Leading Edge Materials Updates Investors on Private Placement

Updated Category News Views 144

Leading Edge Materials Provides Update on Private Placement Leading Edge Materials Corp. (TSXV: LEM) has shared a significant update regarding its previously announced non-brokered private placement. This update is crucial for investors and stakeholders to understand the current status of the financing effort made by the company. The announcement clarifies that, as of the...

Continue Reading
Honoring Excellence in Community Development Financing Innovations

Updated Category News Views 214

Recognizing Leaders in Community Development Finance The Opportunity Honors bring attention to remarkable individuals and organizations shaping communities through dedicated efforts in community development finance. These awards shine a light on those who are committed to fostering economic growth and opportunity for all. Acknowledging the Contributions of Key Figures At...

Continue Reading